These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

132 related articles for article (PubMed ID: 6217862)

  • 1. Extrahypothalamic vasopressin is unchanged in Parkinson's disease and Huntington's disease.
    Rossor MN; Hunt SP; Iversen LL; Bannister R; Hawthorn J; Ang VT; Jenkins JS
    Brain Res; 1982 Dec; 253(1-2):341-3. PubMed ID: 6217862
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Extrahypothalamic vasopressin in human brain.
    Rossor MN; Iversen LL; Hawthorn J; Ang VT; Jenkins JS
    Brain Res; 1981 Jun; 214(2):349-55. PubMed ID: 7237175
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunocytochemical studies of substance P and leucine-enkephalin in Huntington's disease.
    Marshall PE; Landis DM; Zalneraitis EL
    Brain Res; 1983 Dec; 289(1-2):11-26. PubMed ID: 6198034
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Huntington's chorea. Deficiency of gamma-aminobutyric acid in brain.
    Perry TL; Hansen S; Kloster M
    N Engl J Med; 1973 Feb; 288(7):337-42. PubMed ID: 4345566
    [No Abstract]   [Full Text] [Related]  

  • 5. Huntington's disease is accompanied by changes in the distribution of somatostatin-containing neuronal processes.
    Marshall PE; Landis DM
    Brain Res; 1985 Mar; 329(1-2):71-82. PubMed ID: 2858256
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alterations in glutathione levels in Parkinson's disease and other neurodegenerative disorders affecting basal ganglia.
    Sian J; Dexter DT; Lees AJ; Daniel S; Agid Y; Javoy-Agid F; Jenner P; Marsden CD
    Ann Neurol; 1994 Sep; 36(3):348-55. PubMed ID: 8080242
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Loss of cannabinoid receptors in the substantia nigra in Huntington's disease.
    Glass M; Faull RL; Dragunow M
    Neuroscience; 1993 Oct; 56(3):523-7. PubMed ID: 8255419
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Distribution of histamine H3-receptor binding in the normal human basal ganglia: comparison with Huntington's and Parkinson's disease cases.
    Goodchild RE; Court JA; Hobson I; Piggott MA; Perry RH; Ince P; Jaros E; Perry EK
    Eur J Neurosci; 1999 Feb; 11(2):449-56. PubMed ID: 10051746
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Loss of striatal histamine H2 receptors in Huntington's chorea but not in Parkinson's disease: comparison with animal models.
    Martínez-Mir MI; Pollard H; Moreau J; Traiffort E; Ruat M; Schwartz JC; Palacios JM
    Synapse; 1993 Nov; 15(3):209-20. PubMed ID: 7904088
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Possible role of neuromelanin in the pathogenesis of Parkinson's disease.
    Mann DM; Yates PO
    Mech Ageing Dev; 1983 Feb; 21(2):193-203. PubMed ID: 6865505
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The fate of striatal dopaminergic neurons in Parkinson's disease and Huntington's chorea.
    Huot P; Lévesque M; Parent A
    Brain; 2007 Jan; 130(Pt 1):222-32. PubMed ID: 17142832
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Alterations of brain neurotransmitter receptor binding in Huntington's chorea.
    Enna SJ; Bennett JP; Bylund DB; Snyder SH; Bird ED; Iversen LL
    Brain Res; 1976 Nov; 116(3):531-7. PubMed ID: 10053
    [No Abstract]   [Full Text] [Related]  

  • 13. Neuromelanin magnetic resonance imaging of locus ceruleus and substantia nigra in Parkinson's disease.
    Sasaki M; Shibata E; Tohyama K; Takahashi J; Otsuka K; Tsuchiya K; Takahashi S; Ehara S; Terayama Y; Sakai A
    Neuroreport; 2006 Jul; 17(11):1215-8. PubMed ID: 16837857
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations in the levels of iron, ferritin and other trace metals in Parkinson's disease and other neurodegenerative diseases affecting the basal ganglia.
    Dexter DT; Carayon A; Javoy-Agid F; Agid Y; Wells FR; Daniel SE; Lees AJ; Jenner P; Marsden CD
    Brain; 1991 Aug; 114 ( Pt 4)():1953-75. PubMed ID: 1832073
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Increased brain histamine levels in Parkinson's disease but not in multiple system atrophy.
    Rinne JO; Anichtchik OV; Eriksson KS; Kaslin J; Tuomisto L; Kalimo H; Röyttä M; Panula P
    J Neurochem; 2002 Jun; 81(5):954-60. PubMed ID: 12065607
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations.
    Bernheimer H; Birkmayer W; Hornykiewicz O; Jellinger K; Seitelberger F
    J Neurol Sci; 1973 Dec; 20(4):415-55. PubMed ID: 4272516
    [No Abstract]   [Full Text] [Related]  

  • 17. Cannabinoid (CB(1)), GABA(A) and GABA(B) receptor subunit changes in the globus pallidus in Huntington's disease.
    Allen KL; Waldvogel HJ; Glass M; Faull RL
    J Chem Neuroanat; 2009 Jul; 37(4):266-81. PubMed ID: 19481011
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reduction in basal ganglia and substantia nigra substance P levels in Huntington's disease.
    Buck SH; Burks TF; Brown MR; Yamamura HI
    Brain Res; 1981 Mar; 209(2):464-9. PubMed ID: 6164436
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Striatal and nigral neuron subpopulations in rigid Huntington's disease: implications for the functional anatomy of chorea and rigidity-akinesia.
    Albin RL; Reiner A; Anderson KD; Penney JB; Young AB
    Ann Neurol; 1990 Apr; 27(4):357-65. PubMed ID: 1972318
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Serotonin-1 receptor binding sites in the human basal ganglia are decreased in Huntington's chorea but not in Parkinson's disease: a quantitative in vitro autoradiography study.
    Waeber C; Palacios JM
    Neuroscience; 1989; 32(2):337-47. PubMed ID: 2531301
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.